● The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
● The company returns high margins, thereby supporting business profitability.
● The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
● Analyst opinion has improved significantly over the past four months.
Weaknesses
● The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
● One of the major weak points of the company is its financial situation.
● The firm trades with high earnings multiples: 23.74 times its 2023 earnings per share.
● The company's "enterprise value to sales" ratio is among the highest in the world.
● The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
● Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
● The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
● The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
● The company's earnings releases usually do not meet expectations.